Literature DB >> 8846085

Fenfluramine depletes serotonin from the developing cortex and alters thalamocortical organization.

C A Bennett-Clarke1, R D Lane, R W Rhoades.   

Abstract

A previous experiment from our laboratory showed that neonatal destruction of cortical serotoninergic (5-HT) axons with 5,7-dihydroxytryptamine (5,7-DHT) reduced the size of the clusters of vibrissae-related thalamocortical axons. This result suggested an important role for 5-HT in thalamocortical development, but could be questioned because of potentially direct toxic effects of 5,7-DHT on thalamocortical axons. In the present study, 5-HT was depleted from the cortex using a different method, neonatal administration of +fenfluramine, and vibrissae-related patches of thalamocortical afferents were measured when animals reached 6 days of age. Fenfluramine reduced cortical 5-HT levels to 93.9 +/- 6.0% of normal (P < 0.01) and decreased the average area of vibrissae-related lamina IV patches by 23.8 +/- 4.4% (P < 0.05). Depletion of 5-HT with +fenfluramine did not significantly reduce body, brain, or cortical weight, or the overall dimensions of the somatosensory cortex. Thus, these results extend our previous studies by showing that thalamocortical organization can be altered when 5-HT is depleted without the potential for direct toxic effects on thalamic axons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846085     DOI: 10.1016/0006-8993(95)00867-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Serotonergic facilitation of synaptic activity in the developing rat prefrontal cortex.

Authors:  Jean-Claude Béïque; Esther M Chapin-Penick; Ljiljana Mladenovic; Rodrigo Andrade
Journal:  J Physiol       Date:  2004-01-23       Impact factor: 5.182

Review 2.  Insights into the complex influence of 5-HT signaling on thalamocortical axonal system development.

Authors:  Esmee S B van Kleef; Patricia Gaspar; Alexandre Bonnin
Journal:  Eur J Neurosci       Date:  2012-05       Impact factor: 3.386

3.  Serotonin mediates cross-modal reorganization of cortical circuits.

Authors:  Susumu Jitsuki; Kiwamu Takemoto; Taisuke Kawasaki; Hirobumi Tada; Aoi Takahashi; Carine Becamel; Akane Sano; Michisuke Yuzaki; R Suzanne Zukin; Edward B Ziff; Helmut W Kessels; Takuya Takahashi
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

Review 4.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

Review 5.  Cortical reorganization after spinal cord injury: always for good?

Authors:  K A Moxon; A Oliviero; J Aguilar; G Foffani
Journal:  Neuroscience       Date:  2014-07-02       Impact factor: 3.590

6.  Serotonergic pharmacotherapy promotes cortical reorganization after spinal cord injury.

Authors:  Patrick D Ganzer; Karen A Moxon; Eric B Knudsen; Jed S Shumsky
Journal:  Exp Neurol       Date:  2012-12-19       Impact factor: 5.330

7.  5-Hydroxytryptophan during critical postnatal period improves cognitive performances and promotes dendritic spine maturation in genetic mouse model of phenylketonuria.

Authors:  Diego Andolina; David Conversi; Simona Cabib; Antonio Trabalza; Rossella Ventura; Stefano Puglisi-Allegra; Tiziana Pascucci
Journal:  Int J Neuropsychopharmacol       Date:  2010-11-01       Impact factor: 5.176

8.  Deletion of Munc18-1 in 5-HT neurons results in rapid degeneration of the 5-HT system and early postnatal lethality.

Authors:  Jacobus J Dudok; Alexander J A Groffen; Ruud F T Toonen; Matthijs Verhage
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

9.  Early-onset behavioral and neurochemical deficits in the genetic mouse model of phenylketonuria.

Authors:  Elena Fiori; Diego Oddi; Rossella Ventura; Marco Colamartino; Alessandro Valzania; Francesca Romana D'Amato; Vibeke Bruinenberg; Eddy van der Zee; Stefano Puglisi-Allegra; Tiziana Pascucci
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.